Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $319.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 120
- 13F valueReported value at the end of Q2 2026
- $335.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$161.3M
- No comparable prior period
- Free cash flow, FY2025
- -$153.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 9.54M
- Shares sold short
- Change
- −75.1K
- −0.8% vs. previous
- Days to cover
- 10.49
- At average daily volume
Superinvestors holding KYTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KYTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kyverna Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 22, 2025 (view filing)11:42 AM ET | Dec 18 | 4 days | Westlake BioPartners Fund I, L.P. and 3 others10% Owner | PPurchase | +133.3K | $7.50 | +$1.00M | +18.1%869.3K after | Duplicate filing |
| Dec 22, 2025 (view filing) | Dec 18 | 4 days | Seidenberg Beth CDirector | PPurchase | +133.3K | $7.50 | +$1.00M | +18.1%869.3K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Walker Karen MarieChief Technology Officer | SSale | −24.0K | $12.20 | −$292.8K | −51.5%22.6K after | 10b5-1 |
| Feb 14, 2024 (view filing)7:04 PM ET | Feb 12 | 2 days | Vida Ventures, LLC and 3 others10% Owner | PPurchase | +253.1K | $22.00 | +$5.57M | New position583 after | 2 lots |
| Feb 14, 2024 (view filing)5:26 PM ET | Feb 12 | 2 days | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | PPurchase | +450.0K | $22.00 | +$9.90M | +16.6%3.16M after | |
| Feb 13, 2024 (view filing) | Feb 12 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +910.0K | $22.00 | +$20.0M | +28.3%4.13M after | |
| Feb 12, 2024 (view filing)5:51 PM ET | Feb 12 | Same day | Rubin Michael P. and 2 othersOther: Former 10% Owner | PPurchase | +450.0K | $22.00 | +$9.90M | New position450.0K after |
Top 10 13F holders, Q2 2026
See all 120 holdersThe largest institutional positions in Kyverna Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 4,244,818 | $37.8M | 20.76% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 4,126,119 | $36.8M | 2.23% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,134,807 | $27.9M | 0.00% | +2,257,729+257.4% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,885,000 | $25.7M | 1.53% | −225,000−7.2% | Reduced |
| AIGH Capital Management LLC | 2,795,797 | $24.9M | 2.26% | +795,797+39.8% | Added |
| Deerfield Management Company, L.P. (Series C) | 2,000,000 | $17.8M | 0.19% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,897,451 | $16.9M | 0.00% | +114,109+6.4% | Added |
| Price T Rowe Associates Inc | 1,186,023 | $10.6M | 0.00% | −369,264−23.7% | Reduced |
| Geode Capital Management, LLC | 1,049,430 | $9.35M | 0.00% | +625,604+147.6% | Added |
| Insight Holdings Group, LLC | 989,054 | $8.81M | 0.67% | 00.0% | Unchanged |
Holders of 5% or more of KYTX
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kyverna Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Westlake BioPartners Fund I, L.P. | 13G/A | 7.80%4.66M shares | – | Nov 12, 20242 filings | Feb 6, 2026 | SEC |
| GordonMD Global Investments LP | 13G | 7.00%3.06M shares | New | Nov 17, 20251 filing | Nov 17, 2025 | SEC |
| Northpond Ventures III, LP | 13G/A | 6.10%3.47M shares | – | Feb 22, 20242 filings | Feb 17, 2026 | SEC |
| Hirschman Orin | 13G | 5.90%3.65M shares | New | Oct 19, 20261 filing | Oct 19, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.10%3.10M shares | New | Jul 29, 20261 filing | Jul 29, 2026 | SEC |